7 min. Read

AstraZeneca’s digital health strategy. Pear and Cognoa studies.

Issue 046.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 56 percent open rate. Here's what's happening this week:

  • Working toward the next long-form report, which will be focused on musculoskeletal (MSK) digital therapeutics companies. (Like many, I was surprised by Hinge Health's $90 million raise earlier this year.) Send tips, rumors, and requests my way if this one is of interest.
  • Livongo abandoned its trademark for "Cuff to Cloud", which was its brand for the voice-enabled health nudging feature it has developed with Amazon's developer tools. Despite the trademark sunsetting, Livongo tells me the voice-enabled feature is still very much a part of its hypertension program.
  • Health Advances' Partner Andrew Matzkin has a worthwhile column outlining the ways the COVID--19 pandemic is likely to shape the future of

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
6 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
6 min. Read
CMS: PDTs have potential. Trials: Big, Koko, GAIA
6 min. Read
Limbix acquisition price tag. Akili fully pivots to OTC.
6 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last